Committed to addressing unmet medical needs through reinventing existing medications
We are a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.
Welcome to Hyloris
We apply our knowhow and technological innovations to existing pharmaceuticals to unlock their hidden potential and address important unmet medical needs. We have built a broad proprietary pipeline of complex value-added reformulated and repurposed products that have the potential to offer significant advantages over currently available medications.
Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain.
Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks.
We bring added value to the healthcare system through reformulation and repurposing, with the goal to change therapy outcomes and dramatically improve the lives of patients around the globe.
Our products +
We have built a broad proprietary portfolio of value-added reformulated and repurposed product candidates by applying our knowhow and technological innovations to existing pharmaceuticals.
Our strategy +
Committed to addressing underserved needs through innovation with the goal to become the leader in number of 505(b)(2) value-added medicines in development.
Investor relations +
Faster innovation at a much lower cost and risk to drive continuous growth and create shareholders’ value.